Compare AVO & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVO | LTGO |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2020 | 2026 |
| Metric | AVO | LTGO |
|---|---|---|
| Price | $11.69 | $15.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $16.50 | ★ $52.25 |
| AVG Volume (30 Days) | ★ 922.9K | 269.1K |
| Earning Date | 09-08-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.92 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,391,200,000.00 | N/A |
| Revenue This Year | $4.60 | N/A |
| Revenue Next Year | $16.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.68 | N/A |
| 52 Week Low | $10.07 | $13.50 |
| 52 Week High | $15.53 | $25.93 |
| Indicator | AVO | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 41.92 |
| Support Level | $10.22 | $14.05 |
| Resistance Level | $13.35 | $16.56 |
| Average True Range (ATR) | 0.49 | 1.25 |
| MACD | -0.04 | 0.23 |
| Stochastic Oscillator | 38.41 | 39.36 |
Mission Produce Inc produces, packs, and distributes mainly Hass avocados to retail, wholesale, and food service customers, offering pre-ripe and ripened fruit tailored to customer specifications through its network of ripening facilities. The Company operates through three segments: Marketing & Distribution, which sources and distributes fruit globally and generates the majority of revenue; International Farming, which owns and operates avocado orchards and supplies fruit mainly to Marketing & Distribution, with operations principally in Peru and Guatemala; and Blueberries, which farms blueberries sold under an exclusive marketing agreement. The Company's operations span Peru, the United States, Guatemala, Mexico, Europe, and Canada.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.